Abstract: A method of creating a pooled platelet lysate product may include obtaining whole blood from a source; separating platelets from the whole blood using a pressurized rotating microfluidic filtration system; creating platelet rich plasma (PRP) by concentrating the platelets in plasma and removing red blood cells and white blood cells using centrifugation; centrifuging the PRP, removing the plasma, and re-suspending the PRP in the lactated ringers solution (LRS) to create concentrated PRP (C-PRP); laser activating the C-PRP to create an activated C-PRP product; freezing and thawing the activated C-PRP product at least 3 times, wherein vortexing and sonication are performed after each thaw; and reconstituting the activated C-PRP in a saline to create a platelet lysate product with a known potency.

Abstract: Provided is a method or the like for producing a composition exhibiting cytocidal activity. This method for producing a composition exhibiting cytocidal activity comprises: culturing malignant tumor-derived cells in a culture medium at least until the cell density reaches a level that does not pose a problem for transfer; replacing, after culturing, the culture medium with a physiological buffer salt solution; and recovering the physiological buffer salt solution after death of the malignant tumor-derived cells is observed morphologically in the physiological buffer salt solution.

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

Abstract: The invention provides xenonucleic acids and synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing crispr mediated genome editing efficiency. The invention also provides methods and compositions for inducing CRISPR/Cas-based gene editing/regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using single guide RNAs (sgRNAs) that have been chemically modified with xeno nucleic acids which enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a sgRNA that has been chemically modified with xeno nucleic acids to correct a mutation in a target gene associated with the genetic disease.

Abstract: The object of the present invention is to provide a material for efficiently obtaining differentiated cells from pluripotent stem cells. That is, the present invention relates to a pluripotent stem cell differentiation-promoting agent containing, as an active ingredient, a ?-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof, and a solvate thereof, and a method for differentiating pluripotent stem cells, including culturing pluripotent stern cells in a culture medium containing a ?-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof, and a solvate thereof.

Abstract: The present invention provides a composition for inhibiting ice recrystallization, including: A nucleic acid structure comprising a scaffold nucleic acid folded at predetermined positions to form a plurality of strands, and a plurality of staple nucleic acids, wherein at least a portion thereof has a complementary sequence to at least a portion of the scaffold nucleic acid, thereby binding to the scaffold nucleic acid to form a double strand. Therefore, it is possible to increase a survival rate of cells due to having excellent effect of inhibiting ice recrystallization upon cryopreservation of the cells, and maintain a texture of food even when using the composition in the freezing of food.

Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Abstract: A notochordal cell matrix solution as a bioactive lubricant in the treatment of Osteoarthritis, more specifically for use as a bioactive lubricant in viscosupplementation. The notochordal cell matrix solution is capable of reducing the pain in osteoarthritic joints.